Company Description

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States.

Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer’s disease, as well as in phase 2b clinical trial to treat aging frailty.

The company was incorporated in 2014 and is headquartered in Miami, Florida.

Longeveron Inc.

Country	United States
Founded	2014
IPO Date	Feb 12, 2021
Industry	Biotechnology
Sector	Healthcare
Employees	38
CEO	Stephen Willard

Contact Details

Address: Life Science & Technology Park, Suite 520 Miami, Florida 33136 United States
Phone	844 470 2550
Website	longeveron.com

Stock Details

Ticker Symbol	LGVN
Exchange	NASDAQ
Stock Type	Common Stock
Share Class	Class A Shares
Fiscal Year	January - December
Reporting Currency	USD
IPO Price	$10.00
CIK Code	1721484
CUSIP Number	54303L203
ISIN Number	US54303L2034
Employer ID	47-2174146
SIC Code	2834

Key Executives

Name	Position
Dr. Joshua Michael Hare FACC, M.D.	Co-Founder, Chief Science Officer and Executive Chairman

Latest SEC Filings

Date	Type	Title
Aug 10, 2026	SCHEDULE 13G	Filing
Jul 29, 2026	8-K	Current Report
Jul 14, 2026	8-K	Current Report
Jul 10, 2026	S-8	Securities to be offered to employees in employee benefit plans
Jul 8, 2026	8-K	Current Report
Jul 6, 2026	8-K	Current Report
Jun 5, 2026	8-K	Current Report
May 20, 2026	ARS	Filing
May 20, 2026	DEFA14A	Additional definitive proxy soliciting materials and Rule 14(a)(12) material
May 20, 2026	DEF 14A	Other definitive proxy statements

View All SEC Filings